Pku Healthcare Corp., Ltd. (China)

Southwest Synthetic Pharmaceutical Corp., Ltd., located in Chongqing, China, is a limited-liability corporation reorganized on the basis of Southwest Synthesis Pharmaceutical Plant, which was established in 1965 and renamed as Southwest Synthetic Pharmaceutical Co., Ltd. in April 1993. The company's A shares were listed on Shenzhen Stock Exchange on June 16, 1997. It is the largest manufacturing, R&D and export enterprise of biopharmaceutical and synthetic pharmaceutical active pharmaceutical ingredients (APIs) and pharmaceutical preparations in western China. It is also the key enterprise of Chinese pharmaceutical industry, national innovative pilot enterprise, key high and new tech enterprise of national Torch Program, the brand leader enterprise supported by Chongqing government. It is the biggest Lovastatin and Sulfonamides manufacturing enterprise in the world. The company has several large-scale pharmaceutical manufacturing bases, including a modernized pharmaceutical site in Chongqing Liangjiang New Area, which meets international GMP standards. It has hundreds of APIs and preparations which span more than 20 categories, including antimicrobials, cardiovascular treatments, vitamins, anti-inflammatories, immunosuppressive products and plasma volume expanders. It is one of the top pharmaceutical enterprises owning the most certifications in China. All products of this company have been GMP certified. Twenty products have US DMFs and twelve products have been the subject of successful US FDA site inspections. Seven products have been granted CEP. As of December 31, 2010, the company had four major subsidiaries, which involved in manufacture and sale of chemical products and chemical pharmaceuticals.